Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1557 of 5804
-
Supercharged immune cells take on tough cancers in early human test
Disease control OngoingPatients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CATCH T cells, a new experimental treatment. The body has different wa…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New radiation technique aims to spare rectal cancer patients from surgery
Disease control Recruiting nowThis study is a prospective, open-label, phase I design.
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Custom 3D stents aim to make breathing easier and safer
Symptom relief Recruiting nowAirway stenting is usually efficient to treat central airway obstruction but can lead to severe and potentially lethal complications (stent migration, obstructive granuloma, perforation, and hemoptysis). 3D customized airway stents (computer-aided conception using CT-scan data),…
Phase: NA • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Immune drug atezolizumab tested before bladder cancer surgery
Disease control Recruiting nowThis study is being carried out to see if the drug atezolizumab can reduce the size of tumours in patients with types of urothelial cancer before surgery. Atezolizumab is designed to stop a protein called PD-L1 (programmed death-ligand 1) being expressed on the cancer, allowing t…
Phase: PHASE2 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Better scans could cut unnecessary antibiotics in elderly pneumonia cases
Diagnosis CompletedIntroduction: Pneumonia is a leading cause of mortality and a common indication for antibiotic in elderly patients. However, its diagnosis is often inaccurate. The investigators aim to compare the diagnostic accuracy, the clinical and cost outcomes and the use of antibiotics asso…
Phase: NA • Sponsor: University Hospital, Geneva • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail shows promise for tough stomach cancers
Disease control Completed1. Objective 1) Primary Objective: To estimate preliminary overall response rate (ORR) of combination therapy of Ramucirumab and Pembrolizumab in patients with metastatic gastric or GEJ adenocarcinoma 2)Secondary Objectives: To assess secondary measures of clinical efficacy *…
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a common heartburn drug be the key to slowing a deadly lung disease?
Disease control Recruiting nowIPF is a progressive scarring lung condition causing coughing and breathlessness. IPF patients often have reflux disease meaning stomach acid may be breathed into the lungs, potentially damaging them. Medicines which stop stomach acid production, proton pump inhibitors (PPIs), ca…
Phase: PHASE3 • Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Ancient herbal remedy tested to boost IVF success
Symptom relief Recruiting nowThe purpose of this study is to investigate whether oral Gushen Antai pills supplementation for luteal phase support will improve ongoing pregnancy rate in women with normal ovarian reserve in fresh embryo transfer cycles.
Phase: PHASE4 • Sponsor: Shandong University of Traditional Chinese Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Cheaper rituximab versions just as safe and effective for rare vasculitis?
Disease control CompletedThe goal of this multicentre observational study is to compare the safety and effectiveness of rituximab biosimilars to the originator in Canadian patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), two main forms of ANCA-associated vasculitis…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Brain pacemaker learns to help Parkinson's patients walk better
Disease control OngoingThis is a single-center phase I clinical study aiming to improve gait functions in patients with Parkinson's disease (PD) by using adaptive neurostimulation to the pallidum. The investigators will use a bidirectional deep brain stimulation device with sensing and stimulation capa…
Phase: NA • Sponsor: Doris Wang, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill targets rare cancer gene in last-resort patients
Disease control Recruiting nowThis is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New shot every 12 weeks could help men with advanced prostate cancer
Disease control Recruiting nowMedicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in th…
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Personalized plans boost survival odds for older stem cell patients
Disease control CompletedThis clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo targets Hard-to-Treat esophageal cancer
Disease control OngoingCDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.
Phase: PHASE1, PHASE2 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy shows promise for hard-to-treat leukemia
Disease control CompletedThis phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia. Chemotherapy drugs, such as uproleselan, cladribine, and low dose cytarab…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Phone-Based therapy may lift mood in expectant moms
Symptom relief OngoingThe main objective of the current research project is to evaluate the effectiveness of the digitalized cognitive behavioral therapy program including telephone coaching for antenatal depressive symptoms. The participants are screened from the general population of pregnant women,…
Phase: NA • Sponsor: University of Turku • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New hope for incurable germ cell tumors? cabozantinib trial underway
Disease control OngoingThe purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject…
Phase: PHASE2 • Sponsor: Jennifer King • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Tough-to-Treat prostate cancer
Disease control CompletedTo evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 16:18 UTC
-
Ovarian cancer vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedPhase I study to evaluate safety and systemic immunogenicity of the DCP-001 vaccine in patients with high grade serous ovarian cancer after primary treatment.
Phase: PHASE1 • Sponsor: University Medical Center Groningen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
Experimental antibody targets childhood cancers in first human trial
Disease control Recruiting nowThe purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC